ITH

DOCKET NO.: JJPR-0032

**PATENT** 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Lovenberg, et al.

Confirmation No.: 1837

**Application No.: 10/626,445** 

Group Art Unit: 1653

Filing Date: July 23, 2003

**Examiner: Not Yet Assigned** 

For: DNAs ENCODING MAMMALIAN HISTAMINE RECEPTOR OF THE H4

**SUBTYPE** 

DATE OF DEPOSIT: October 5, 2004

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA,

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

## INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of

D I 116	J 991 K 0052					
	the above identified	application as set forth in § 1.491, before the mailing date				
	of a first Office Action on the merits of the above-identified application, or					
	before the mailing date of a first Office Action after the filing of request for					
	continued examinati	ion under § 1.114, no additional fee is required.				
		§ 1.129(a), this Information Disclosure Statement is being				
	filed in connection with [ ] the first or [ ] second After Final Submission,					
	therefore:					
	☐ Cert	ification in Accordance with § 1.97(e) is attached; or				
	The fee of \$180.00 as set forth in § 1.17(p) is attached.					
	In accordance with § 1.97(c), this Information Disclosure Statement is being					
ليا	filed after the period set forth in § 1.97(b) above but before the mailing date of					
		on under § 1.113 or a Notice of Allowance under § 1.311, or				
	before an action that otherwise closes prosecution in the application, therefore:					
		Certification in Accordance with § 1.97(e) is attached;				
		or				
		The fee of $$180.00$ as set forth in § 1.17(p) is attached.				
	In accordance wi	th § 1.97(d), this Information Disclosure Statement is being				
	filed after the mailing date of either a Final Action under § 1.113 or a Notice					
	of Allowance under § 1.311 but before, or simultaneously with, the payment					
	of the Issue Fee, therefore included are: Certification in Accordance with §					
	1.97(e); and the s	submission fee of \$180.00 as set forth in § 1.17(p).				

	Copies of each of the references listed on the attached Form PTO-1449 are				
	enclosed herewith.				
$\boxtimes$	Copies of references listed on the attached Form PTO-1449 are enclosed				
	herewith				
$\boxtimes$	Copies of references listed on the attached Form PTO 1449 are not required to				
_	be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR §				
	1.98(a)(2)(i).				
	EXCEPT THAT:				
	In view of the voluminous nature of references [list as appropriate],				
	and the likelihood that these references are available to the Examiner,				
	copies are not enclosed herewith.				
	In accordance with § 1.98(d), copies of the following references listed				
	on the attached Form PTO-1449 are not enclosed herewith because				
	they were previously cited by or submitted to the U.S. Patent and				
	Trademark Office in patent application(s) for which a claim for priority				
	under 35 U.S.C.§ 120 have been made in the instant application:				
	Copies of references [list as appropriate] listed on the				
	attached Form PTO-1449 were previously cited by or submitted				
	to the Patent and Trademark Office in prior Application No.				
	, filed ·				

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date: October 4,2004

Scott E. Scioli

Registration No. 47,930

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2004 WW





Form PTO	-1449 Modified	Docket No. JJPR-0032	Application No. 10/626,445			
Cited b	t and Publications by Applicant sheets if necessary)	Applicant Lovenberg, et al.				
U.S. Departr Patent and	OTHER DOCUMENTS (Including Novel Class (H3) of Histan		Group 1653			
ОТНЕ	R DOCUMENTS (Includ	ling Author, Title	e, Date, Pertinent Pages, Etc.)			
	Arrang, J-M. et al., "Aut Novel Class (H3) of His	to-Inhibition of Bratamine Receptor",	ain Histamine Release Mediated by a Nature(London), April 1983, 302, 832-			
2	2 Clark, M.A. et al., "Guanine Nucleotides and Pertussis Toxin Reduce the Affinit Histomine H3 Recentors on AtT-20 Cells", Agents Actions, 1993, 40, 129-134					
3	Clark, M.A. et al., "High Affinity Histamine H3 Receptors Regulate ACTI Release by AtT-20 Cells" Furgpean Journal of Pharmacology, 1992, 210, 31-35					
4	De Vos, C., "H1-Receptor Antagonists: Effects on Leukocytes, Myth of Reality					
5	Gantz, I. et al., "Molecu	llar Cloning of a G 784 1 <b>991</b> 88 429	ene Encoding the Histamine H2 Receptor,			
6	Hill, S.J. et al., "Interna	tional Union of Ph Pharmacological I	larmacology. XIII. Classification of Reviews, <b>1997</b> , 49(3), 253-278			
7	Kohler, G., et al. "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" Nature, 1975, 256, 495-497					
	Koning, M. et al. "Method for Identifying Ligands that Bind to Cloned Gs-of Gl-Coupled Recentors" Molecular and Cellular Neurosciences, 1991, 2, 331-337					
9	Lovenberg, T.W. et al., "Cloning and Functional Expression of the Human Histamme H3 Pecenter" Molecular Pharmacology, 1999, 55, 1101-1107					
10	Mikayama Tetal "M	olecular Cloning and Inhibiting Factor	r', Proc. Natl. Acad. Sci. USA, 1993, 90,			
EXAMINER		DA'	TE CONSIDERED			

Form PTO-1449 Modified			Docket No JJPR-003		Application No. 10/626,445		
C	Department of Commerce		Applicant Lovenberg, et al.				
			Filing Dat July 23, 2		Group 1653		
O	ГНЕ	R DOCUMENTS (Includ	ing Author	, Title, Date, I	Pertinent Pages, Etc.)		
·	11	Oda, T. et al., "Molecula Histamine Receptor Pref Biological Chemistry, 20	erentially E	xpressed in Le	ukocytes", The Journal of		
	12						
	13	Raible, D.G. et al., "Phar on Human Eosinophils",	_		on of a Novel Histamine Receptor ed, 1994, 1506-1511		
	14	Voet, D. et al., Biochemi	stry, John V	Viley & Sons, I	nc., <b>1990,</b> 126-127-228-233		
	15	Yamashita, M. et al., "Ex Histamine H1 Receptor"					
_		:	<del></del>				
-							
<b>EXAMINER</b>				DATE CONS	SIDERED		

Form PTO-1449 Modified				Docket No.  JJPR-0032	Application No. <b>10/626,445</b>		
	Cite	ent and Publications d by Applicant al sheets if necessary		Applicant Lovenberg, et al.			
U.S. Department of Commerce Patent and Trademark Office			;	Filing Date July 23, 2003	Group 1653		
· · · · · · · · · · · · · · · · · · ·		U.	S. PATEN	T DOCUMENTS			
Examiner Initial		Document No.	Date	Name		Class	Subclass
	16	5,817,480	10/06/98	Murry, et al.		435	69.1
	17	5,882,893	03/16/99	Goodearl		435	69.1
	18	5,885,824	03/23/99	Yamada, et al.		435	252.3
	19	6,136,559	10/24/00	Lovenberg, et al.		435	69.1
	20	6,204,017 B1	03/20/01	Behan, et al.		435	69.1
	21	2002/0132755 A1	09/19/02	Jenkinson, et al.		514	1
				`			
		FOR	EIGN PAT	TENT DOCUMEN	TS	Tr	anslation
Examiner Initial		Document No.	Date	Country		YES	NO
	22	WO 01/85786 A2	11/15/01	PCT			
EXAMINI	ER			DATE CONSII	ERED		